Journal article 254 views 46 downloads
Enhanced pyrazolopyrimidinones cytotoxicity against glioblastoma cells activated by ROS-Generating cold atmospheric plasma
,
Clara Charleton,
Robert W. Devine,
Mark Kelada,
John M.D. Walsh,
Gill Conway ,
Sebnem Gunes ,
Julie Rose Mae Mondala ,
Furong Tian,
Brijesh Tiwari,
Gemma K. Kinsella,
Renee Malone ,
Denis O'Shea,
Michael Devereux ,
Wenxin Wang,
Patrick J. Cullen,
John C. Stephens,
James F. Curtin
European Journal of Medicinal Chemistry, Volume: 224, Start page: 113736
Swansea University Author:
Gill Conway
-
PDF | Version of Record
© 2021 The Authors. This is an open access article under the CC BY license.
Download (2.39MB)
DOI (Published version): 10.1016/j.ejmech.2021.113736
Abstract
Pyrazolopyrimidinones are fused nitrogen-containing heterocyclic systems, which act as a core scaffold in many pharmaceutically relevant compounds. Pyrazolopyrimidinones have been demonstrated to be efficient in treating several diseases, including cystic fibrosis, obesity, viral infection and cance...
| Published in: | European Journal of Medicinal Chemistry |
|---|---|
| ISSN: | 0223-5234 |
| Published: |
Elsevier BV
2021
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa65435 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
Pyrazolopyrimidinones are fused nitrogen-containing heterocyclic systems, which act as a core scaffold in many pharmaceutically relevant compounds. Pyrazolopyrimidinones have been demonstrated to be efficient in treating several diseases, including cystic fibrosis, obesity, viral infection and cancer. In this study using glioblastoma U-251MG cell line, we tested the cytotoxic effects of 15 pyrazolopyrimidinones, synthesised via a two-step process, in combination with cold atmospheric plasma (CAP). CAP is an adjustable source of reactive oxygen and nitrogen species as well as other unique chemical and physical effects which has been successfully tested as an innovative cancer therapy in clinical trials. Significantly variable cytotoxicity was observed with IC50 values ranging from around 11 μM to negligible toxicity among tested compounds. Interestingly, two pyrazolopyrimidinones were identified that act in a prodrug fashion and display around 5–15 times enhanced reactive-species dependent cytotoxicity when combined with cold atmospheric plasma. Activation was evident for direct CAP treatment on U-251MG cells loaded with the pyrazolopyrimidinone and indirect CAP treatment of the pyrazolopyrimidinone in media before adding to cells. Our results demonstrated the potential of CAP combined with pyrazolopyrimidinones as a programmable cytotoxic therapy and provide screened scaffolds that can be used for further development of pyrazolopyrimidinone prodrug derivatives. |
|---|---|
| Keywords: |
Cold atmospheric plasma; Pyrazolopyrimidinone; Pro-drug; ROS; Glioblastoma; Programmable cytotoxicity |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
This work is supported by Irish Research Council Government of Ireland Postdoctoral Fellowship Award GOIPD/2020/788 (Z.H., J.C.) and IRCSET EMBARK grant (G.E.C., J.C.); Science Foundation Ireland Grant Numbers 14/IA/2626 (P·C., J.C.) and 17/CDA/4653 (B T., P·C., J.C.); and by the TU Dublin Fiosraigh Scholarship Programme (S·B., J.M., J.C.); Science Foundation Ireland infrastructure grants 16/RI/3399 and 12/RI/2346/SOF; Maynooth University John Hume Scholarship (M.K.); Government of Ireland Postgraduate Scholarship from the Irish Research Council (R. D.); Maynooth University Teaching Studentship (C·C.). |
| Start Page: |
113736 |